Indian drug companies are preparing to launch low-cost versions of Novo Nordisk’s Wegovy and Ozempic as patents expire in 2026, making weight-loss and diabetes treatment more affordable worldwide.

It's estimated that around 1.5 million Brits are now taking weight-loss drugs, such as Wegovy, Ozempic, Mounjaro, Saxenda and Orlistat.

Senior author and NYU Assistant Professor Dr Karan Chhabra on larger studies to address drug efficacy and who could do better ...

Hair loss is becoming a concern for some individuals using weight loss medications such as Ozempic, Wegovy and Zepbound — popular drugs that offer rapid weight loss ...

Most importantly, don’t leave nutrition and exercise out of the equation. There is a huge difference between a healthy and an unhealthy thin person.

A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...

Demand for Mounjaro cannot realistically be metType 2 diabetes medication Mounjaro is less than a week away from being ...

Eli Lilly and Company (NYSE:LLY) may be affected by the CVS formulary change considering it could change how its medication, Zepbound, is viewed when compared to Wegovy. That said, despite possible ...

Type 2 diabetes patients taking semaglutide, often sold as Ozempic or Wegovy, have a slightly lower risk of stroke compared ...

Most people with prediabetes don’t have any symptoms, but darkened skin, skin tags and changes in the eyes could be ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Indian pharmaceutical companies are preparing to flood the market with generic versions of Novo Nordisk’s semaglutide—sold ...